Meningococcal Disease Update in Western Australia: A Comprehensive Overview
A Critical Health Concern
Meningococcal disease, a rare yet life-threatening bacterial infection, has been reported in Western Australia, with four new cases diagnosed in the past two months. This update aims to provide essential information to the public, emphasizing the importance of awareness and prevention.
Understanding the Disease
Meningococcal disease is a severe illness caused by the bacteria Neisseria meningitidis, which can infect the blood, spinal cord membranes, and brain. It can also affect other areas, such as the throat, lungs, and joints. The disease is not common, but its potential for rapid progression and severe complications demands attention.
2025 Statistics
In 2025, 13 cases of invasive meningococcal disease were reported, with serogroup B being the most prevalent (12 cases) and serogroup Y accounting for one case. Unfortunately, one individual succumbed to the disease, similar to the numbers reported in 2024.
Current Cases and Monitoring
The recent diagnosis of four individuals with serogroup B meningococcal disease does not indicate an immediate increase in case numbers. However, the Department of Health is closely monitoring this notifiable disease to ensure prompt action if necessary.
Vaccination Options
Two types of meningococcal vaccines are available in Western Australia. The first protects against four serogroups (A, C, W, and Y), while the second focuses on serogroup B. The MenACWY vaccine is offered free to all children at 12 months and Year 10 students, with a catch-up program for adolescents aged 15-19.
Targeted Vaccination for Aboriginal Children
Recognizing the higher incidence of meningococcal disease among Aboriginal children, the MenACWY vaccine is provided free to Aboriginal children aged 6 weeks to 12 months, and the MenB vaccine is available at no cost for all Aboriginal children up to the age of two.
Vaccination for High-Risk Individuals
Individuals with specific medical risk conditions can access both vaccines at no charge, discussed with their healthcare provider. Those not eligible for free vaccines can request them through their healthcare provider for a fee.
Meningococcal Bacteria and Transmission
Meningococcal bacteria are not easily transmitted from person to person. They are present in droplets from the nose and throat during coughing or sneezing but are not spread by saliva and do not survive long in the environment.
Approximately 10-20% of the population carries the bacteria harmlessly in the back of the nose and throat at any given time. Serious infections occur very rarely when the bacteria invade the bloodstream or tissues.
Symptoms and Urgent Medical Attention
Symptoms of invasive meningococcal disease may include high fever, chills, headache, neck stiffness, nausea, vomiting, drowsiness, confusion, and severe muscle and joint pain. A distinctive spotty red-purple rash may also appear.
Young children may not exhibit symptoms, making fever, pale complexion, vomiting, lethargy, poor feeding, and rash crucial indicators. Despite being treatable with antibiotics, the disease can progress rapidly, emphasizing the need for urgent medical attention for anyone displaying these symptoms.
Potential Long-Term Complications
While most individuals recover with appropriate treatment, meningococcal disease can be fatal in 5-10% of cases. Around 15% of survivors may experience long-term complications, such as hearing loss, limb amputations, or brain damage.
Further Information
For comprehensive details on meningococcal disease, visit Healthy WA (https://www.healthywa.wa.gov.au/Articles/J_M/Meningococcal-disease).
Media Contact
For media inquiries, contact WA Health Media at media@health.wa.gov.au.
